Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis
Liêm Binh Luong Nguyen(Institut Pasteur), Yusuke Shimakawa(Kumamoto Health Science University), Shevanthi Nayagam(Imperial College London), Umberto D’Alessandro(MRC Unit the Gambia), Timothy B Hallet(Imperial College London), Zachary J. Ward(Harvard University), Maud Lemoine(MRC Unit the Gambia), Gibril Ndow(MRC Unit the Gambia), Mark Thursz(Imperial College Healthcare NHS Trust)
Cited by 21
Related Papers
Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
|New England Journal of Medicine|2019|2k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Association between an MHC Class II Allele and Clearance of Hepatitis B Virus in the Gambia
|New England Journal of Medicine|1995|439